Fintech

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Wsj·April 7, 2026 at 12:50 PM

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.

Original Source

Wsj — www.wsj.com

Related in Fintech

Consumers Pull Back on Credit Card Spending
PYMNTS
CZ recounts SBF's desperate FTX collapse requests
CoinDesk
Bitcoin Surges Past $72,000 on Ceasefire News
CoinDesk
Legion Health AI Gets Utah Approval for Prescription Refills
PYMNTS

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Consumers Pull Back on Credit Card Spending

CZ recounts SBF's desperate FTX collapse requests

Bitcoin Surges Past $72,000 on Ceasefire News

Legion Health AI Gets Utah Approval for Prescription Refills